ArticleInternational journal of antimicrobial agents2015
Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus.
Article in International journal of antimicrobial agents, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2021Pooled it
- Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.JAMA dermatology · 2018Trial
- Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Molecular epidemiology of methicillin-resistantFrontiers in microbiology · 2025Review
- Sequencing a CC239-MRSA-III with a novel composite SCC mec element from Kuwait.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Clinical relevance of topical antibiotic use in co-selecting for multidrug-resistantAntimicrobial agents and chemotherapy · 2023Article
- Characterisation of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Antibacterial Activities of Homemade Matrices Miming Essential Oils Compared to Commercial Ones.Antibiotics (Basel, Switzerland) · 2021Article
- Characterisation of S. aureus/MRSA CC1153 and review of mobile genetic elements carrying the fusidic acid resistance gene fusC.Scientific reports · 2021Article
- Clonal Lineages, Antimicrobial Resistance, and PVL Carriage ofAntibiotics (Basel, Switzerland) · 2021Article
- Epidemiological typing of methicillin resistantInfection prevention in practice · 2021Article
- Fusidic Acid Resistance Determinants in Methicillin-Resistant Staphylococcus aureus Isolated in Kuwait Hospitals.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
- Genotyping of methicillin resistant Staphylococcus aureus from the United Arab Emirates.Scientific reports · 2020Article
- Perceived utility and feasibility of pathogen genomics for public health practice: a survey among public health professionals working in the field of infectious diseases, Belgium, 2019.BMC public health · 2020Article
- Using genomics to understand meticillin- and vancomycin-resistantMicrobial genomics · 2020Review
- Emergence of Methicillin-ResistantInfection and drug resistance · 2020Article
- Status and potential of bacterial genomics for public health practice: a scoping review.Implementation science : IS · 2019Article
- Genetic resistance determinants to fusidic acid and chlorhexidine in variably susceptible staphylococci from dogs.BMC microbiology · 2019Article
- Characterisation of a novel SCCmec VI element harbouring fusC in an emerging Staphylococcus aureus strain from the Arabian Gulf region.PloS one · 2019Article
- The effect of antimicrobial additives on the properties of dental glass-ionomer cements: a review.Acta biomaterialia odontologica Scandinavica · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
Fusidic acid is a topical and systemic antimicrobial used for the treatment of staphylococcal infections in hospitals and the community. Sales of fusidic acid and resistance rates among meticillin-resistant Staphylococcus aureus (MRSA) doubled between 1990 and 2001. For the following decade, fusidic acid resistance rates among isolates from Addenbrooke's Hospital (Cambridge, UK) were compared with national resistance rates from MRSA bacteraemia surveillance data and with antimicrobial sales data. Sales of fusidic acid remained relatively constant between 2002 and 2012, whilst fusidic acid resistance increased two- and four-fold in MRSA bacteraemias nationally and in MRSA isolates from Cambridge, respectively. A subgroup of MRSA resistant only to fusidic acid increased after 2006 by 5-fold amongst bacteraemias nationally and 17-fold (to 7.7% in 2012) amongst Cambridge MRSA isolates. All of the available local isolates from 2011 to 2012 (n=23) were acquired in the community, were not related epidemiologically and belonged to multilocus sequence typing (MLST) groups ST1, 5, 8, 45 or 149 as revealed from analysis of whole-genome sequence data. All harboured the fusC gene on one of six distinct staphylococcal cassette chromosome (SCC) elements, four of which were dual-resistance chimeras that encoded β-lactam and fusidic acid resistance. In summary, fusidic acid-resistant MRSA increased in prevalence during the 2000s with notable rises after 2006. The development of chimeric cassettes that confer dual resistance to β-lactams and fusidic acid demonstrates that the genetics underpinning resistance in community-associated MRSA are evolving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.